Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862483 | 0.95 | HTR1A (0.50) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL9413613 | 0.85 | HTR1A (0.56) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL27297827 | 0.83 | LTB4R (0.54) | HTR1ADRD2TP53CYP1A2CYP3A4 | |
| SCHEMBL3023099 | 0.82 | THRA (0.48) | CYP1A2CYP3A4CYP2C9L3MBTL1LMNA | |
| SCHEMBL8862583 | 0.81 | DRD2 (0.56) | HTR1ADRD2ABCB1KCNH2 | |
| SCHEMBL7855263 | 0.81 | THRA (0.50) | CYP1A2CYP3A4CYP2C9L3MBTL1LMNA | |
| SCHEMBL7470362 | 0.80 | LTB4R (0.62) | PTGER1PTGER4PTGER3PTGER2CYP2C9 | |
| SCHEMBL8317233 | 0.80 | DRD2 (0.50) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL10650358 | 0.80 | HTR1A (0.50) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL9828737 | 0.79 | THRA (0.52) | CYP1A2CYP3A4CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522657-B | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-15 | — | — | CN | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-1993339-B | Aromatic compound | OTSUKA PHARMA CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| CN-101522657-A | STAT3/5 activation inhibitor | OTSUKA PHARMA CO LTD (JP) | 2009-09-02 | — | — | CN | disclosed |
| EP-2089373-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-19 | — | — | EP | disclosed |
| CN-101321529-A | Diaryl aether derivant as antineoplastic agent | OTSUKA PHARMA CO LTD (JP) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | HTR1A 325/4885DRD2 189/4885PTGER1 1133/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | HTR1A 3067/4885DRD2 3573/4885PTGER1 2464/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | HTR1A 3437/4885DRD2 3690/4885PTGER1 2058/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | HTR1A 343/4885DRD2 1486/4885PTGER1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.